April 14, 2026
Introduction: India Strengthens Digital Health Regulation
In October 2025, the Central Drugs Standard Control Organization (CDSCO) released a draft guidance on Medical Device Software (MDS) under the Medical Device Rules, 2017.
This long-awaited guidance provides regulatory clarity for software-based medical technologies, reinforcing India’s alignment with global digital health regulations while supporting innovation in AI-driven healthcare, SaMD, and connected medical devices.
Regulatory Scope: SaMD & SiMD Clearly Defined
The CDSCO guidance establishes a structured approach for regulating:
- Software as a Medical Device (SaMD)
- Software in a Medical Device (SiMD)
Aligned with global frameworks (e.g., IMDRF principles), the guidance ensures:
- Clear distinction between standalone and embedded software
- Inclusion of mobile apps, cloud platforms, and AI-enabled tools
- Applicability across diagnostics, monitoring, and therapeutic software
Risk-Based Classification Framework (Class A–D)
A risk-based classification system has been introduced, consistent with existing Indian regulations:
| Class | Risk Level | Regulatory Expectations |
| Class A | Low Risk | Basic documentation & QMS |
| Class B | Low-Moderate | Enhanced technical documentation |
| Class C | Moderate-High | Clinical evaluation + validation |
| Class D | High Risk | Full regulatory scrutiny & approvals |
Key Requirements Across Classes
- Quality Management System (QMS) aligned with ISO 13485
- Clinical Evaluation & Performance Data
- Software Verification & Validation (V&V)
- Risk Management (ISO 14971 alignment)
Emerging Technologies: AI/ML, Cybersecurity & Cloud
The CDSCO guidance reflects next-generation regulatory priorities:
1. AI/ML-Based Medical Software
- Emphasis on algorithm transparency and explainability
- Continuous learning systems require change control mechanisms
- Focus on data integrity and bias mitigation
2. Cybersecurity Requirements
- Secure software architecture expectations
- Protection against data breaches and cyber threats
- Lifecycle cybersecurity risk management
3. Cloud & Connected Devices
- Validation of cloud infrastructure and data storage
- Compliance with data privacy and localization norms
- Real-time monitoring and interoperability considerations
Lifecycle Approach: Total Product Lifecycle (TPLC) Compliance
The guidance adopts a lifecycle-based regulatory model, ensuring safety beyond approval:
Pre-Market Phase
- Software design validation
- Clinical performance evaluation
- Risk assessment documentation
Post-Market Phase
- Post-Market Surveillance (PMS)
- Periodic Safety Update Reports (PSURs)
- Real-world performance monitoring
Change Management
- Controlled handling of:
- Software updates
- Version upgrades
- AI model modifications
Regulatory Pathways & Licensing in India
The guidance clarifies market access pathways without introducing new regulatory burdens:
- Licensing under existing CDSCO framework
- Defined documentation requirements:
- Device Master File (DMF)
- Plant Master File (PMF)
- Software documentation (architecture, V&V reports)
- Alignment with import and manufacturing licensing routes
India vs Global Regulatory Alignment (2026 Perspective)
| Aspect | India (CDSCO) | Global Trend |
| SaMD Definition | IMDRF-aligned | Standardized globally |
| AI/ML Regulation | Emerging guidance | FDA/EMA evolving frameworks |
| Cybersecurity | Increasing focus | Mandatory in US/EU |
| Lifecycle Approach | Strengthening PMS | TPLC widely adopted |
Strategic Implications for Industry
- Growing need for digital health regulatory strategy in India
- Increased investment in software validation & cybersecurity compliance
- Expansion of AI/ML regulatory documentation frameworks
- Stronger integration of global regulatory harmonization practices
Outlook: India’s Digital Health Regulatory Evolution
India is moving toward:
- Dedicated AI/ML regulatory frameworks
- Integration with digital health missions & interoperability standards
- Stronger real-world evidence (RWE) utilization
- Alignment with global SaMD lifecycle regulations
India is positioning itself as a high-growth, innovation-driven digital health market with structured regulatory oversight.
Conclusion: Balancing Innovation & Compliance
CDSCO’s MDS guidance is a major step forward in creating a transparent, risk-based, and globally aligned regulatory ecosystem for software-driven healthcare solutions.
For manufacturers and innovators, success will depend on:
- Early regulatory strategy planning
- Robust software lifecycle documentation
- Alignment with global standards (IMDRF, ISO, IEC)
- Continuous post-market compliance
Call to Action
How do you see India’s approach to regulating digital health evolving in the coming years?
Share your thoughts or connect with experts at Maven Regulatory Solutions for:
- India market entry strategy
- CDSCO medical device software registration
- AI/ML regulatory compliance
- End-to-end regulatory support
FAQs
1. What is Medical Device Software (MDS) under CDSCO?
MDS includes software intended for medical purposes, including SaMD and SiMD, regulated under India’s Medical Device Rules, 2017.
2. How is SaMD classified in India?
Based on risk (Class A–D), considering intended use and potential patient impact.
3. Does CDSCO regulate AI-based medical software?
Yes, the draft guidance includes considerations for AI/ML, focusing on transparency, validation, and lifecycle control.
4. What are post-market requirements for MDS?
Post-market surveillance, software updates management, and ongoing safety monitoring are mandatory.
Post a comment